Retatrutide, a novel dual activator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) binding site , is exhibiting promising results in preliminary clinical trials . Recent https://cyberbookmarking.com/story21288333/retatrutide-emerging-studies-and-possible-clinical-uses